StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.16−0.02 (-0.28%)

Close on Nov 20, 2026Market cap $472.65MP/E –Yield –

Regenxbio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Regenxbio's free cash flow for the twelve months ending Jun 30, 2026 was -$249.67M. For fiscal 2025 it was -$126.38M. The highest annual figure on record is $134.70M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$126.38M–
FY2024Dec 31, 2024-$175.56M–
FY2023Dec 31, 2023-$228.37M–
FY2022Dec 31, 2022-$238.21M-276.8%
FY2021Dec 31, 2021$134.70M–
FY2020Dec 31, 2020-$80.93M–
FY2019Dec 31, 2019-$119.43M-230.7%
FY2018Dec 31, 2018$91.37M–
FY2017Dec 31, 2017-$65.15M–
FY2016Dec 31, 2016-$56.71M–
FY2015Dec 31, 2015-$23.04M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$63.00M–
Q1 FY2026Mar 31, 2026-$77.42M-337.5%
Q4 FY2025Dec 31, 2025-$52.80M–
Q3 FY2025Sep 30, 2025-$56.45M–
Q2 FY2025Jun 30, 2025-$49.73M–
Q1 FY2025Mar 31, 2025$32.61M–
Q4 FY2024Dec 31, 2024-$32.70M–
Q3 FY2024Sep 30, 2024-$40.88M–
Q2 FY2024Jun 30, 2024-$45.97M–
Q1 FY2024Mar 31, 2024-$56.01M–
Q4 FY2023Dec 31, 2023-$41.89M–
Q3 FY2023Sep 30, 2023-$50.85M–
Q2 FY2023Jun 30, 2023-$49.90M–
Q1 FY2023Mar 31, 2023-$85.74M–
Q4 FY2022Dec 31, 2022-$44.84M-113.7%
Q3 FY2022Sep 30, 2022-$55.51M–
Q2 FY2022Jun 30, 2022-$70.99M–
Q1 FY2022Mar 31, 2022-$66.88M–
Q4 FY2021Dec 31, 2021$326.88M+1129.9%
Q3 FY2021Sep 30, 2021-$61.20M–
Q2 FY2021Jun 30, 2021-$55.91M–
Q1 FY2021Mar 31, 2021-$75.07M–
Q4 FY2020Dec 31, 2020$26.58M–
Q3 FY2020Sep 30, 2020-$42.53M–
Q2 FY2020Jun 30, 2020-$24.77M–
Q1 FY2020Mar 31, 2020-$40.20M–
Q4 FY2019Dec 31, 2019-$26.54M–
Q3 FY2019Sep 30, 2019-$31.83M–
Q2 FY2019Jun 30, 2019-$29.30M-143.4%
Q1 FY2019Mar 31, 2019-$31.75M-156.9%
Q4 FY2018Dec 31, 2018-$9.03M–
Q3 FY2018Sep 30, 2018-$22.93M–
Q2 FY2018Jun 30, 2018$67.54M–
Q1 FY2018Mar 31, 2018$55.79M–
Q4 FY2017Dec 31, 2017-$15.93M–
Q3 FY2017Sep 30, 2017-$17.59M–
Q2 FY2017Jun 30, 2017-$11.23M–
Q1 FY2017Mar 31, 2017-$20.41M–
Q4 FY2016Dec 31, 2016-$24.86M–
Q3 FY2016Sep 30, 2016-$14.04M–

More Regenxbio figures

See a number that looks wrong?